On October 27, 2015, Stemline Therapeutics, Inc. and Eric Rowinsky, M.D. agreed to a separation whereby he would depart from his position as the company's Executive Vice President, Chief Medical Officer and Head of Research and Development. Dr. Rowinsky will continue to serve as a consultant to the company.
Stemline Therapeutics, Inc.
Equities
US85858C1071
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+18.41% | 124B | |
+18.02% | 111B | |
-11.88% | 23.17B | |
+5.07% | 22.94B | |
-39.94% | 17.42B | |
-10.14% | 17.42B | |
-14.97% | 16.9B | |
+3.07% | 13.71B | |
+26.74% | 11.82B |